Description: Lasa Supergenerics Limited engages in the research, manufacture, and marketing of animal and human healthcare products in India. It offers API products comprising fenbendazole, toldimphos sodium, cyromazine, albendazole, ricobendazole, oxfendazole, closantel base, closantel sodium dihydrate BP, nitroxynil, rafoxanide, oxyclozanide, ornidazole, and halquinol, as well as 2,6-diiodo-4-nitrophenol; and other API products. The company also provides animal feed ingredients, including calcium iodate; and reagents for therapeutic use, such as potassium iodide. In addition, it exports its products. Lasa Supergenerics Limited was incorporated in 2016 and is based in Ratnagiri, India.
Home Page: lasalabs.com
Plot no. C-4
Ratnagiri,
415722
India
Phone:
91 96 0797 3801
Officers
| Name | Title |
|---|---|
| Dr. Omkar Pravin Herlekar | Chairman & MD |
| Ms. Mitti Jain C.S. | Company Secretary & Compliance Officer |
| Mr. Umesh Shankar Pawar | Additional Executive Director |
| Ms. Varsha Pravin Joshi | Chief Financial Officer |
| Mr. Anil Fargade | Senior Accounts Officer |
| Mr. Sunil Sitale | Manager of HR & Admin |
Exchange: NSE
Country: IN : India
Currency: Indian Rupee (INR)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.468 |
| Price-to-Sales TTM: | 1.2729 |
| IPO Date: | |
| Fiscal Year End: | March |
| Full Time Employees: | 77 |